Skin toxicity in BRAF(V600) mutated metastatic cutaneous melanoma patients treated with vemurafenib
Introduction: The use of orally available BRAF kinase inhibitor – vemurafenib is associated with numerous adverse skin reactions. Aim: To assess the safety and early side effects of vemurafenib treatment in the unselected group of patients treated at the outpatient clinic, in particular the as...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2016-02-01
|
| Series: | Advances in Dermatology and Allergology |
| Subjects: | |
| Online Access: | https://www.termedia.pl/Skin-toxicity-in-BRAF-V600-mutated-metastatic-cutaneous-melanoma-patients-treated-with-vemurafenib,7,24295,1,1.html |